Authors: Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC.
DOI:10.3329/jbcps.v38i0.47512
Abstract
Background: A definitive treatment of SARS CoV-2 is yet toarrive and the human death toll rises exponentially globally.In this health emergency, it might be useful to look into theold therapies which could be effective against the virus. Invitro research showed Ivermectin could decrease theconcentration of coronavirus 4000 to 5000 folds in livinglung tissue.Aim: In this prospective study a combination of Ivermectinand Doxycycline will be evaluated therapeutically to treatCOVID-19 patients.Methods: 100 COVID-19 patients were enrolled in this studywith a predefined inclusion and exclusion criteria. RT- PCRof the SERS-CoV-2 will be done at designated governmenthospitals. The clinical features and response to treatmentwere noted according to a dedicated protocol.Results: In this study male and female were 64 and 36respectively, the age ranged between 8 to 84 years. Retestingwas done between 4 and 18 days of starting medication. Allpatients tested negative and their symptoms improved within72 hours. There were no noticeable side effects.Conclusion: Combination of Ivermectin and doxycyclinewas found to be very effective in viral clearance in mild andmoderately sick COVID-19 patients. Medical societies andinstitutions should undertake larger multi center studies tovalidate and recommend this combination therapy to includein national guidelines
Keywords: Covid-19, Doxycycline, Ivermectin
